Tyra Biosciences, Inc. (TYRA)
21.50
-0.25
(-1.15%)
USD |
NASDAQ |
Oct 29, 16:00
21.49
-0.01
(-0.05%)
After-Hours: 20:00
Tyra Biosciences Enterprise Value : 949.19M for Oct. 28, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 28, 2026 | 949.19M |
| October 27, 2026 | 935.47M |
| October 26, 2026 | 869.84M |
| October 23, 2026 | 871.63M |
| October 22, 2026 | 896.69M |
| October 21, 2026 | 880.58M |
| October 20, 2026 | 872.82M |
| October 19, 2026 | 805.40M |
| October 16, 2026 | 756.48M |
| October 15, 2026 | 787.50M |
| October 14, 2026 | 767.22M |
| October 13, 2026 | 758.87M |
| October 12, 2026 | 820.91M |
| October 09, 2026 | 841.20M |
| October 08, 2026 | 842.99M |
| October 07, 2026 | 868.05M |
| October 06, 2026 | 859.10M |
| October 05, 2026 | 900.27M |
| October 02, 2026 | 870.44M |
| October 01, 2026 | 905.04M |
| September 30, 2026 | 956.35M |
| September 29, 2026 | 962.91M |
| September 28, 2026 | 931.29M |
| September 25, 2026 | 949.79M |
| September 24, 2026 | 988.57M |
| Date | Value |
|---|---|
| September 23, 2026 | 1.037B |
| September 22, 2026 | 1.177B |
| September 21, 2026 | 1.182B |
| September 18, 2026 | 1.187B |
| September 17, 2026 | 1.109B |
| September 16, 2026 | 1.104B |
| September 15, 2026 | 1.169B |
| September 14, 2026 | 1.147B |
| September 11, 2026 | 965.90M |
| September 10, 2026 | 1.056B |
| September 09, 2026 | 964.70M |
| September 08, 2026 | 1.246B |
| September 04, 2026 | 1.361B |
| September 03, 2026 | 1.135B |
| September 02, 2026 | 1.151B |
| September 01, 2026 | 1.161B |
| August 31, 2026 | 1.145B |
| August 28, 2026 | 1.140B |
| August 27, 2026 | 1.211B |
| August 26, 2026 | 1.216B |
| August 25, 2026 | 1.244B |
| August 24, 2026 | 1.208B |
| August 21, 2026 | 1.206B |
| August 20, 2026 | 1.184B |
| August 19, 2026 | 1.251B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 8.272B |
| Oncolytics Biotech, Inc. | 51.37M |
| Sangamo Therapeutics, Inc. | 40.63M |
| Sarepta Therapeutics, Inc. | 2.298B |
| Anixa Biosciences, Inc. | 101.59M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -45.56M |
| Total Expenses (Quarterly) | 45.56M |
| EPS Diluted (Quarterly) | -0.6904 |
| Earnings Yield | -11.13% |
| Normalized Earnings Yield | -11.13 |